

FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD


Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant _____Jonaki Bose_____

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

No conflicts

Signature _____
 _____

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

**FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting**

July 10-11, 2017
Silver Spring, MD


Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant ____Boyer_____

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

none

Signature _____


Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant **John T. Brooks**

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

None

Signature



Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD


Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant _____ Daniel Budnitz _____

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

No conflicts

Signature 

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant Theresa Cassidy

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

Theresa Cassidy is an employee of Inflexxion, Inc. Inflexxion has contracts to conduct post-market surveillance and studies of prescription medication abuse with various pharmaceutical companies.

Signature 

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD


Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant Daniel Ciccarone MD, MPH

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

No Conflicts

Signature 

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant _____ Wilson M. Compton _____

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

Dr. Compton reports long term, minimal stock holdings in Pfizer Inc., General Electric Co., and 3M Companies unrelated to the meeting topic.

Signature _____

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant __Frederick Conrad_____

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

NONE

Signature__  _____

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD


Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant Elizabeth H. Crane

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

No conflicts.

Signature 

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:


Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant: Nabarun Dasgupta, MPH, PhD

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

ND is a part-time employee of the RADARS System.

Signature _____



Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant Carol DeFrances

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

No conflicts

Signature Carol DeFrances

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:


Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant: Louisa Degenhardt

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

I have received investigator-initiated untied educational grants from Reckitt Benckiser/Indivior for studies of buprenorphine-naloxone, buprenorphine depot, naloxone, the development of an opioid-related behaviour scale, and a study of opioid substitution therapy uptake among chronic non-cancer pain patients. I have received investigator-initiated untied educational grants for the conduct of post-marketing surveillance of a potentially tamper-resistant formulation of controlled-release oxycodone from Mundipharma.

Signature



Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant Barry I Graubard

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

Own stock in Medtronics

Signature 

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant Jody L. Green

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

I have no personal conflicts of interest. All research and consulting funding is awarded to my employer, the Denver Health and Hospital Authority (DHHA), a political subdivision of the State of Colorado. DHHA independently owns and operates the RADARS System which is supported by subscriptions from pharmaceutical manufacturers for surveillance, research and reporting services.

Signature 

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

**FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting**

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant Holly Hedegaard, MD, MSPH

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

No conflicts.

Signature Holly Hedegaard MD

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant Christopher M. Jones

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

no conflicts

Signature 

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

**FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting**

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:


Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant _____ Erin E. Krebs _____

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

No conflicts.

Signature _____



Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD


Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant Peter W. Kreiner

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

No conflicts.

Signature 

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:


Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant __ Vincent Lo Re __

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

AstraZeneca: saxagliptin

International Society for Pharmacoepidemiology, Board of Directors

Signature  6/26/2017

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant F Leland McClure, MSci, PhD, F-ABFT

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

Employed by Quest Diagnostics

Consult for SAMHSA Workplace Drug Testing, Research Triangle Institute, RTP, NC

Signature 

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant Richard Miech

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

No conflicts

Signature Richard Miech

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant Scott P. Novak

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

Endo Pharmaceuticals, Indivior, PLC, Pfizer, Shire, Purdue, Zogenix,

Signature  June 13/2017

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant Jennifer Parker

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

No conflicts

Signature JFD Parker

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant Dr. Elizabeth J. Scharman

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

No conflicts.

Signature *Elizabeth J. Scharman*

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant ____Sidney H. Schnoll, MD, PhD_____

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

I am an employee of Pinney Associates, Inc., which consults with numerous pharmaceutical companies on the development and post-marketing surveillance of abuse deterrent opioid products.

Signature__  _____

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant Abigail Shoben

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

No conflicts

Signature 

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant George Jay Unick

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

No Conflicts

Signature 

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Data and Methods for Evaluating the Impact of Opioid Formulations
With Properties Designed to Deter Abuse in the Postmarket Setting

July 10-11, 2017
Silver Spring, MD

Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Public Meeting: Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket Setting. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant __Almut Winterstein_____

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state “no conflicts”, sign and return the form.

No conflicts

Signature_____

Please email the form to Cherice Holloway (Cherice.Holloway@fda.hhs.gov) by June 23, 2017.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.